Loading ...

Sai Kanaparthi

Immune Tolerance Network

Assessment Group

skanaparthi@immunetolerance.org

Work:

(240)235-6101

Mobile:

Address:

Immune Tolerance Network

Committees:

,

Studies:

ITN029ST

-

Withdrawal of Immunosuppression in Pediatric Liver Transplant Recipients

ITN030ST

-

Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant

ITN036ST

-

Renal Allograft Tolerance through Mixed Chimerism

ITN039ST

-

Research Study of ATG and Rituximab in Renal Transplantation

ITN041AI

-

A Research Trial of Aralast in New Onset Diabetes

ITN054ST

-

BMT and High Dose Post-Transplant Cyclophosphamide for Chimerism Induction and Renal Allograft Tolerance

ITN056ST

-

Evaluation of Donor Specific Immune Senescence and Exhaustion as Biomarkers of Tolerance Post Liver Transplantation

ITN063ST

-

A Cohort Study of Operationally Tolerant Allograft Recipients

ITN069ST

-

Renal Allograft Tolerance Through Mixed Chimerism And Co-Stimulation Blockade With Belatacept

ITN075AI

-

Brentuximab Vedotin for Systemic Sclerosis

ITN079AD

-

Vaginal Microbiome Exposure and Immune Responses in C-section Infants

ITN524ST-CTOT-12

-

Associating Renal Transplantation With the ITN Signature of Tolerance

ITN803ST

-

Donor-Alloantigen-Reactive Regulatory T Cell (darTregs) in Liver Transplantation (deLTa)

ITN823ST

-

Immunosuppression Withdrawal for Stable Pediatric Liver Transplant Recipients

ITN826AI

-

Pilot Clinical Trial of Ustekinumab in Patients With New-onset T1D

Bio:

Admin Links

Shortcuts

ITN Documents

Links